To address this question, we examined several prominent changes that progressed throughout the disease, using another mouse model of SCA2 with human ATXN2-Q58 transgenic overexpression under control of the Purkinje cell specific Pcp2 promoter [78], shortly named Q58-Tg here. The gene discussed is ATXN2; the disease is spinocerebellar ataxia type 2.